Basic Documentation of Adalimumab (Humira) in Patients With Ankylosing Spondylitis (AS)

Study Identifier
P10-147
CT.gov Identifier
NCT01079182
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Axial Spondyloarthritis (axSpA)
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    1. Participants with active, AS for at least 4 weeks (BASDAI greater than or equal to 4). 2. Participants who failed treatment with two non-steroidal anti-inflammatory drugs (NSAIDs). 3. No contraindications for anti-tumor necrosis factors (TNF) therapy.
    Exclusion Criteria:
    1\. Participants who do not meet the above listed inclusion criteria.

    Protocol Summary

    The research question explored in this study was whether the effectiveness and safety of adalimumab in participants with ankylosing spondylitis was maintained during long-term therapy in routine clinical practice in Germany.

    Study Locations

    No locations found.